Job Title: Partner | Co-Chair, Cannabis Law Practice | Vice Chair, Food and Beverage Practice
Company: Saul Ewing Arnstein & Lehr LLP
Location: Baltimore, MD | Washington, D.C.
Jonathan Havens’s practice focuses primarily on regulatory, compliance, enforcement, and transactional matters related to products regulated by the U.S. Food and Drug Administration (FDA), the U.S. Drug Enforcement Administration (DEA), and myriad state and local agencies. He counsels state cannabis and hemp license applicants and awardees, ancillary service and product providers, investors, management companies, and various other entities that are affected by federal and state marijuana laws, such as long-term care facilities and higher education institutions.Jonathan is co-chair of the Cannabis Law Practice at Saul Ewing Arnstein & Lehr LLP. He also serves as vice chair of the firm’s Food and Beverage Practice and is a member of the firm’s Life Sciences Practice. Jonathan’s unique perspective on cannabis regulation is informed by his congressional, federal agency, and national and international law firm experience. Prior to entering private practice, Jonathan served as a regulatory counsel with FDA, where he focused on compliance and enforcement related to promotion, advertising, and labeling. Prior to law school, Jonathan was a legislative aide in both the U.S. Senate and U.S. House of Representatives.
It cannot be denied that the 2018 Farm Bill becoming law is a significant development. At long last, the confusing legal and regulatory status of hemp will start to be clarified. However, this clarity will not come overnight, as USDA could take at least a year to issue regulations. How long USDA will take to craft its regulations is but one open question, a few others are: how rigorous will USDA be when reviewing longstanding state hemp programs; will processors and marketers be able to prove to DEA’s satisfaction that their products are hemp-derived rather than marijuana-derived; will FDA look the other way when firms selling CBD-infused foods, dietary supplements, and cosmetic products take advantage of an exploding market but do not make aggressive disease claims; and will FDA issue a regulation allowing the use of hemp-derived CBD in foods and dietary supplements. Jonathan Havens, a former Capitol Hill staffer and FDA regulator, will explore the answers to these and many other questions, and will arm attendees with the information they need to make an informed decision about operating in or entering the hemp and hemp-derived products spaces.
Named to the Food and Drug Law Institute’s (FDLI) Cannabis-Derived Products Committee, 2019
Named to the National Law Journal’s Cannabis Law Trailblazers list, 2018
Recipient of The Daily Record’s Generation J.D. Leadership in Law Award, 2018
Named to the Maryland Super Lawyers “Rising Stars” List for Food and Drugs, 2018 to present
Named to the Washington, D.C. Super Lawyers “Rising Stars” List for Food and Drugs, 2016 – 2018
FDA Group Recognition Award, 2011
FDA Center for Tobacco Products Team Excellence Award, 2011